offer
all report title image

Noninvasive prenatal testing (NIPT) is an evolving screening procedure for pregnant women. It examines cell free Deoxyribonucleic Acid (DNA) of both fetus and the mother. It provides an analysis of genetic screening using only one tube blood. NIPT provides predictions about the absence or presence of genetic abnormality in the fetus. It involves a simple method of blood withdrawal but presents high quality effectiveness for the detection of trisomy by minimizing the number of performing further invasive testing procedures. NIPT is performed to detect certain genetic abnormalities such as missing or extra copies of X and Y chromosomes, trisomy 18, trisomy 13, and Down syndrome. With technological advancements in the near future, NIPT will be able to detect other genetic abnormalities.

North Africa non-invasive prenatal testing market is estimated to be valued at US$ 2,796 million in 2021 and is expected to exhibit a CAGR of 8.7% over the forecast period (2021-2028).

Figure 1. North Africa Non-invasive Prenatal Testing Market Share (%), By Application, 2021

North Africa Non-Invasive Prenatal Testing  | Coherent Market Insights

The increasing adoption of inorganic strategies such as strategic collaborations is expected to drive the growth of North Africa non-invasive prenatal testing market over the forecast period.

For instance, in June 2017, Illumina, Inc., an American company, collaborated with Next Generation Genomic Co., Ltd., the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science. This alliance will allow large patient access to Illumina under next-generation sequencing for NIPT.

CMI table icon

North Africa Non-invasive Prenatal Testing Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 2,796 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 8.7% 2028 Value Projection: US$ 4,759 Mn
Geographies covered:
  • Region: Egypt, Algeria, Morocco, and Rest of North Africa
Segments covered:
  • By Application: Trisomy, Microdeletion Syndrome, Sex Chromosome Abnormalities, Others
  • By End User: Hospitals, Diagnostic Centers & Independent Laboratories
Companies covered:

Illumina, Inc., Eurofins Scientific, PerkinElmer, Inc., F. Hoffmann-La Roche AG, Natera, Inc., Yourgene Health Plc., Laboratory Corporation of America Holdings (LabCorp), BGI Group, and Quest Diagnostics Incorporated

Growth Drivers:
  • The strong focus of key players on entering the North African market
  • High prevalence of abnormalities in pregnancies and birth defects 
Restraints & Challenges:
  • Presence of alternative methods for prenatal diagnosis
  • Risk of claiming false test results

Figure 2. North Africa Non-invasive Prenatal Testing Market Share (%), By End User, 2021

North Africa Non-Invasive Prenatal Testing  | Coherent Market Insights

Increasing product launches are expected to drive the market growth over the forecast period.

For instance, in May 2017, Natera Inc., a clinical genetic testing company, launched ‘Vistara’, a non-invasive prenatal test (NIPT). It is designed to screen single-gene disorders.

North Africa Non-invasive Prenatal Testing Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization (WHO), over 265,713,467 cases and 5,260,888 deaths due to the coronavirus were reported till December 07, 2021 across the globe.

The COVID-19 pandemic and subsequent lockdown in various countries have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, it is expected to have a significant impact on North Africa non-invasive prenatal testing (NIPT) market, in terms of both demand and supply.

Society for Maternal-Fetal Medicine (SMFM) suggests that, the number of ultrasound appointments in the first trimester can be reduced by performing one ultrasound examination for dating and nuchal translucency (NT) to reduce the chances of COVID-19 exposure. NIPT can be performed at home utilizing remote services such as mobile blood draw networks. This will help maintain expectant mother’s safety during the pandemic with minimum social contact.

North Africa Non-invasive Prenatal Testing Market Restraint

The presence of alternative methods for prenatal diagnosis is expected to be a major factor hindering the North Africa non-invasive prenatal testing market growth over the forecast period.

For instance, amniocentesis and chorion biopsy are two alternative methods that are used in prenatal diagnosis. Amniocentesis is a medical test used for prenatal diagnosis and sex determination. Chorion biopsy, also known as Chorionic villus sampling (CVS), is another diagnostic test performed during pregnancy to determine if an unborn child is at risk of congenital defects.

NIPT based on cell-free DNA analysis from maternal blood is a screening test with certain chances of false positive and negative results. Furthermore, NIPT does not screen birth defects such as open neural tube defects or other conditions such as autism. NIPT tests also do not screen for polyploidy (e.g. triploidy) or single gene disorders. Such limitations are expected to hamper the growth of North Africa non-invasive prenatal testing market.

Key Players

Major players operating in North Africa non-invasive prenatal testing market include Illumina, Inc., Eurofins Scientific, PerkinElmer, Inc., F. Hoffmann-La Roche AG, Natera, Inc., Yourgene Health Plc., Laboratory Corporation of America Holdings (LabCorp), BGI Group, and Quest Diagnostics Incorporated.

Noninvasive prenatal testing (NIPT) is also known as noninvasive prenatal screening (NIPS). It is a procedure used to determine the chromosomal abnormalities or disorders of the fetus which generally occur due to missing or an extra copy (aneuploidy) of a chromosome. NIPT examines small DNA fragments which are circulating in the blood of pregnant woman. These small fragments are freely floating and hence are called cell-free DNA. NIPT is carried out for the detection of trisomy 18, trisomy 13, Down syndrome, and missing or extra copies of X and Y chromosomes. NIPT is found to be useful during the COVID-19 pandemic situation to avoid the risk of infection. The potential to isolate fetal DNA and fetal cells from maternal blood during pregnancy has revealed exciting opportunities for upgraded noninvasive prenatal testing (NIPT).

Market Dynamics

The strong focus of key players on entering the North African market, and increasing awareness about the adoption of non-invasive prenatal testing are the major factors that are expected to drive the growth of North Africa non-invasive prenatal testing market over the forecast period.

For instance, according to the data published by National Library of Medicine in May 2020, twenty five studies in 9 sub-Saharan African countries manifested that the prevalence of birth defects was 20.40 per 1,000 births.

Moreover, in March 2019, Yourgene Health Plc, an international molecular diagnostics group, arranged an event in Egypt to increase the awareness of IONA test, a non-invasive prenatal DNA test performed for Down syndrome.

Key features of the study:

  • This report provides an in-depth analysis of North Africa non-invasive prenatal testing market, market size (US$ Mn.), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in North Africa non-invasive prenatal testing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Illumina, Inc., Eurofins Scientific, PerkinElmer, Inc., F. Hoffmann-La Roche AG, Natera, Inc., Yourgene Health Plc, Laboratory Corporation of America Holdings (LabCorp), BGI Group, Quest Diagnostics Incorporated
  • Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • North Africa non-invasive prenatal testing market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the

Detailed Segmentation:

  • North Africa Non-invasive Prenatal Testing Market, By Application:
    • Trisomy
    • Microdeletion Syndrome
    • Sex Chromosome Abnormalities
    • Others
  • North Africa Non-invasive Prenatal Testing Market, By End User:
    • Hospitals
    • Diagnostic Centers & Independent Laboratories
  • North Africa Non-invasive Prenatal Testing Market, By Country:
    • Egypt
      • By Application
        • Trisomy
        • Microdeletion Syndrome
        • Sex Chromosome Abnormalities
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers & Independent Laboratories
    • Algeria
      • By Application
        • Trisomy
        • Microdeletion Syndrome
        • Sex Chromosome Abnormalities
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers & Independent Laboratories
    • Morocco
      • By Application
        • Trisomy
        • Microdeletion Syndrome
        • Sex Chromosome Abnormalities
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers & Independent Laboratories
    • Rest of North Africa
      • By Application
        • Trisomy
        • Microdeletion Syndrome
        • Sex Chromosome Abnormalities
        • Others
      • By End User
        • Hospitals
        • Diagnostic Centers & Independent Laboratories
  • Company Profiles
    • Illumina, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Eurofins Scientific
    • PerkinElmer, Inc.
    • Hoffmann-La Roche AG
    • Natera, Inc.
    • Yourgene Health Plc
    • Laboratory Corporation of America Holdings (LabCorp)
    • BGI Group
    • Quest Diagnostics Incorporated

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

North Africa non-invasive prenatal testing market size is estimated to be valued at US$ 2,796 million in 2021 and is expected to exhibit a CAGR of 8.7% between 2021 and 2028.
Increasing product launches, increasing adoption of inorganic strategies such as strategic collaborations are expected to drive the market growth over the forecast period.
Trisomy segment is expected to hold a major market share, owing to the rising adoption of inorganic strategies such as collaborations by key players during the forecast period.
Egypt holds the largest share in the market.
Major factors hampering the growth of the market include the presence of alternative methods for prenatal diagnosis and risk of claiming false test results.
Major players operating in the market include Illumina, Inc., Eurofins Scientific, PerkinElmer, Inc., F. Hoffmann-La Roche AG, Natera, Inc., Yourgene Health Plc., Laboratory Corporation of America Holdings (LabCorp), BGI Group, and Quest Diagnostics Incorporated.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo